ERFURT, Germany and BERLIN and VORARLBERG, Austria, May 12, 2021 / CNW / – AMP Alternative Medical Products Inc. (Frankfurt: C4TA) (ISIN: CA0318961038) (CSE: XCX), a pharmaceutical supplier of medical cannabis products to German pharmacies and Dr. Feurstein Medical Hemp GmbH (“HANAFSAN”), an Austrian pharmaceutical CBD hemp manufacturer, have concluded a supply agreement for the import and sale of HANAFSAN-certified CBD hemp cosmetics in Germany.
AMP will import a range of pharmaceutical grade CBD cosmetics under the brand name HANAFSAN for sale in Germany. These cosmetics are made from hemp grown organically in Europe and are processed and manufactured in their EU-GMP-compliant facility in Vorarlberg, Austria. HANAFSAN CBD cosmetic products are already certified for sale in Germany without a doctor’s prescription.
HANAFSAN CBD oils are made from high-quality full-spectrum hemp extracts, which are made from certified EU hemp varieties and formulated into cold-pressed organic hemp seed oil in accordance with EU pharmaceutical standards. HANAFSAN CBD creams use hemp extract from the leaves of approved EU hemp varieties and formulate with a cold-pressed organic hemp seed oil, shea butter and aloe vera, which can achieve a revitalizing and moisturizing effect. Dr. Feurstein Medical Hemp Extract Oil for Oil Pulling is a dentist recommended product that can support dental and oral health problems.
Click here to view HANAFSAN’s products: https://www.hanafsan.com/cbd-produkte/
From mid-May 2021, the AMP sales team will sell hemp extract CBD oils for cosmetic devices in 5%, 10%, 15% CBD concentration and hemp extract creams in 0.3% and 3% CBD concentration in various volume sizes and “Dr . Feurstein Medical hemp extract oil for oil pulling “in 0.3% CBD concentration.
Dr. Daniel Feurstein, CEO and Founder of HANAFSAN, said: “With the approval of CBD as a narcotic in the EU, we wanted a strong German partner to represent our brand, the largest market in Europe. AMP’s sales team was trained in the benefits of medicinal products Cannabis and cover all important sales regions in Germany. ”
Dr. Stefan Feuerstein, President and Director of AMP, commented: “We have just completed our sales training, in which representatives from HANAFSAN presented their products to our team. We are assuming that sales of CBD medical and consumer goods in Germany will start this year will grow exponentially. We wanted our first certified CBD product to be a high quality product that our sales team could offer to our pharmacy customers. “
About HANAFSAN from Dr. Feurstein
HANAFSAN is a brand of Dr. Feurstein Medical Hemp GmbH, an innovative and scientifically oriented manufacturer of certified CBD hemp products and organic hemp foods that are grown and produced in the EU. The pharmaceutical company based in Altach (Austria) has HANAFSAN branches in Götzis (Austria) and Konstanz (Germany) as well as a warehouse in Zurich (Switzerland). The products are Austria Bio Guarantee certified and bear the certification mark of the Austrian Chamber of Commerce “Cosmetics manufacturer with certified know-how”. The translation of the name of HANAFSAN is: HANAF, which means hemp in Old High German, and SAN means “to heal” in Latin.
More information is available at www.hanafsan.com.
AMP Alternative Medical Products Inc. (formerly AMP German Cannabis Group Inc.) is a pharmaceutical narcotics supplier of medical cannabis for German pharmacies with branches in Erfurt and Berlin. AMP works in accordance with the German Narcotics Act (BtMG) and the Free State of Thuringia and ensures that medical cannabis products imported by AMP from all over the world and sold in Germany meet the EU GMP standard (Good Manufacturing Practice). AMP’s national sales force represents medical and commercial cannabis product brands from Aphria, Bedrocan, Little Green Pharma and HANAFSAN.
The AMP Roundtable Series discusses topics related to medical cannabis in Germany and is available as a podcast and video. In episode 2 “Politics and Medical Cannabis in Germany”, Dr. Wieland Schinnenburg, Member of the Bundestag (FDP), a current overview of the political problems and challenges of the medical cannabis industry in Germany. Find out more at www.amp-eu.de/roundtable.
To learn more about the European cannabis industry, download AMP’s Prohibition Partners sponsored report. https://prohibitionpartners.com/reports/the-european-cannabis-report-6th-edition/
Further information can be found at www.amp-eu.com.
Neither the CSE nor its regulatory service provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this press release.
This press release contains forward-looking statements based on the company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including its business plans and milestones and their timing. Although the company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, these statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. As a result, actual results and results could differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date they are made and the company undertakes no obligation to publicly update them to reflect new information or the occurrence of future events or circumstances, unless otherwise required by law.
SOURCE AMP Alternative Medical Products Inc.
© Canada Newswire, source Canada Newswire English